Infection Risk During Targeted and Biologic Therapies in Rheumatoid Arthritis and Psoriatic Arthritis
An overview of the risk for infections during targeted and biologic therapies in rheumatoid arthritis and psoriatic arthritis.
An overview of the risk for infections during targeted and biologic therapies in rheumatoid arthritis and psoriatic arthritis.
Rheumatologist Jeff Stark, MD, discusses the diagnostic code developed specifically for nonradiographic axial spondyloarthritis.
Dr Brian LaMoreaux emphasized the importance of screening, addressing manifestations, and physician education in improving patient outcomes in gout.
Jemima Albayda, MD, discusses the cardiac complications in idiopathic inflammatory myopathies.
Barriers to pharmacotherapy for osteoporosis warrant further investigation in order to reduce the elevated mortality and morbidity rates associated with the disease.
Research has consistently demonstrated racial and ethnic disparities among patients with rheumatoid arthritis. Rheumatology Advisor interviewed one of the authors of a recent study, Isabel Castrejon, to learn more about these disparities and any potential solutions.
An expert from the Division of Rheumatology and Clinical Immunology at the University of Pittsburgh discusses reproductive health and family planning in women with rheumatic diseases.
A greater understanding of the mechanisms that promote hypertension in rheumatic diseases will provide insight into understanding primary hypertension.
Research has shown that Disease Activity Scores are inflated as a result of pain reports that do not reflect actual disease activity in rheumatoid arthritis.